

Surgeons in Cancer Diagnostics and Therapy

June 18–20, 2009

Hyatt Regency Bonaventure, Weston, FL

Introduction

New imaging technologies and genomic and proteomic methodologies for the treatment of cancer are significantly changing the role of surgical oncologists.

Surgical oncologists are working even more closely with laboratory scientists, medical oncologists, and radiation oncologists to further develop

- new laboratory and imaging diagnostics
- novel therapeutics that target specific cell growth pathways expressed in a primary tumor
- methods for tissue acquisition
- neoadjuvant treatments for resectable primary tumors
- diagnostics that lead to personalized cancer treatment

This program will provide a greater understanding of the surgical oncologist's changing role in cancer diagnostics and how new procedures will affect practice.

Objectives

1. To understand the role of surgeons in cancer diagnostics.
2. To understand results of novel procedures that could affect a surgeon's practice.
3. To understand the direction of novel adjuvant therapies that affect surgically resectable disease.

Audience

General surgeons, surgical oncologists, thoracic surgeons, nurses, clinical research coordinators, and patient advocates

Thursday, June 18

- 5:00–6:30 pm Information desk open for questions
- 6:30–7:30 pm Reception for attendees and speakers (location to be announced)
Dinner is not provided.

Friday, June 19

- 6:30–7:30 am Breakfast buffet and registration
Grand ABC
- 7:30 am–12:00 pm **Plenary Session: The Role of the Surgeon in Cancer Diagnostics**
Amphitheater
- Opening remarks and introduction
 - Audience educational assessment
 - Educational objective: to understand how surgeons will incorporate diagnostics into cancer care

8:00–10:00 am

Gastrointestinal Cancers

- Neoadjuvant therapy for locally advanced esophageal cancer
Speaker: Carolyn Reed, MD
- Surgeon's role in mutational analysis of KRAS in colorectal cancer: implications for systemic adjuvant therapy
Speaker: George Chang, MD

Thoracic Cancers

- The role of surgeons in identifying chemoresistance to adjuvant therapy for NSCLC
Speaker: Matthew J. Schuchert MD, FACS
- What are the standard biomarkers that surgeons should request for thoracic malignancies and what are research biomarkers?
Speaker: Ramaswamy Govindan, MD
- Q & A
- Audience educational reassessment

10:00–10:30 am

Break in exhibit area

10:30 am–12 pm

Breast Cancers

- What is the clinical significance of micrometastases in a sentinel lymph node?
Speaker: Lee Wilke, MD
- RT-PCR to detect metastases in sentinel nodes: comparison to current intraoperative methods
Speaker: Peter Blumencranz, MD
- Surgeons and gene expression profiling of breast cancer
Speaker: John Olson, MD
- Q & A
- Audience educational reassessment

12:00–1:00 pm

Buffet lunch
Grand ABC

1:00–5:00 pm

New Procedures in Surgical Oncology

1:00–2:45 pm

- Surgical outcomes of SLN biopsy in Z10 and Z11 protocols
Speaker: Anthony Lucci, MD
- *In situ* ablation of breast tumors
Speaker: Rache Simmons, MD
- Q & A

2:45–3:00 pm

Break in exhibit area

- 3:00–5:00 pm - Lymph node dissection for NSCLC: node sampling or mediastinal dissection
Speaker: Bryan Meyers, MD
- Extent and quality of lymphadenectomy in esophageal cancer resection
Speaker: Bryan Meyers, MD
 - Controversies in sublobar resection of NSCLC
Speaker: Francis Nichols, MD
 - Laparoscopic resection of cancer of the colon and rectum: techniques and controversies
Speaker: James Fleshman, MD
 - Q & A

Dinner is not provided.

Saturday, June 20

- 6:30–7:30 am Breakfast buffet
Society Lounge
- 7:30 am–12:00 pm **Novel Neoadjuvant and Adjuvant Therapies in Surgical Patients**
Amphitheater
- 7:30–9:40 am - Introduction and audience educational assessment
- Novel surgical methods to resect rectal cancer after neoadjuvant chemoradiation therapy
Speaker: Julio Garcia-Aguilar, MD
 - Adjuvant therapies of resected pancreatic cancer
Speaker: Vincent Picozzi, MD
 - The impact of neoadjuvant therapies for HER2neu+ breast cancers on surgical care
Speaker: Aman Buzdar, MD
 - Q & A
 - Audience educational reassessment
- 9:40–10:00 am Break in exhibit area
- 10:00 am–12 pm - Neoadjuvant Therapies for DCIS: Why and Who?
Moderator: Henry Kuerer, MD
- Knowledge assessment of audience

- Neoadjuvant endocrine therapy

Speaker: Shelley Hwang, MD

- Neoadjuvant administration of pegylated doxorubicin via the nipple duct

Speaker: Lisa Jacobs, MD

- Neoadjuvant trastuzumab

Speaker: Henry Kuerer, MD

- Q & A

- Knowledge reassessment of audience

12–1:00 pm

Lunch presentation (location to be announced)

- Partnering with cooperative groups and your hospital to bring clinical trials to your patients

Speaker: Gary Unzeitig, MD

Please see the Concierge for optional activities such as tennis, golf, beachcombing, tours, kayaking, and shopping.